These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 1695522

  • 1. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
    Seckl MJ, Rustin GJ, Bagshawe KD.
    Br J Cancer; 1990 Jun; 61(6):916-8. PubMed ID: 1695522
    [Abstract] [Full Text] [Related]

  • 2. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
    de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Vermeylen K, Stoter G.
    Br J Cancer; 1997 Jun; 75(3):432-5. PubMed ID: 9020492
    [Abstract] [Full Text] [Related]

  • 3. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
    Price P, Hogan SJ, Bliss JM, Horwich A.
    Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
    [Abstract] [Full Text] [Related]

  • 4. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
    Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W.
    Eur J Cancer; 1993 Apr; 29A(7):961-5. PubMed ID: 7684597
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ, Norman AR, Dearnaley DP, Horwich A.
    J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
    Inanç SE, Meral R, Darendeliler E, Yasasever V, Onat H.
    Acta Oncol; 1999 Jan; 38(4):505-9. PubMed ID: 10418719
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours.
    Lancet; 1985 Jan 05; 1(8419):8-11. PubMed ID: 2578205
    [Abstract] [Full Text] [Related]

  • 8. Serum tumour marker regression rate following chemotherapy for malignant teratoma.
    Horwich A, Peckham MJ.
    Eur J Cancer Clin Oncol; 1984 Dec 05; 20(12):1463-70. PubMed ID: 6209145
    [Abstract] [Full Text] [Related]

  • 9. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.
    Price P, Hogan SJ, Horwich A.
    Eur J Cancer; 1990 Apr 05; 26(4):450-3. PubMed ID: 1694086
    [Abstract] [Full Text] [Related]

  • 10. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ.
    J Clin Oncol; 2001 May 01; 19(9):2534-41. PubMed ID: 11331333
    [Abstract] [Full Text] [Related]

  • 11. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH, Sleijfer DT, Schraffordt Koops H, De Bruijn HW, Oosterhuis JW, Brouwers TM, Ockhuizen T, Marrink J.
    Oncodev Biol Med; 1981 May 01; 2(1-2):117-28. PubMed ID: 6170952
    [Abstract] [Full Text] [Related]

  • 12. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
    de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G.
    Br J Cancer; 1998 Nov 01; 78(10):1350-5. PubMed ID: 9823978
    [Abstract] [Full Text] [Related]

  • 13. Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis.
    Raghavan D, Peckham MJ, Heyderman E, Tobias JS, Austin DE.
    Br J Cancer; 1982 Feb 01; 45(2):167-73. PubMed ID: 6174137
    [Abstract] [Full Text] [Related]

  • 14. Serum tumor markers and testicular germ cell tumors: a primer for radiologists.
    Marshall C, Enzerra M, Rahnemai-Azar AA, Ramaiya NH.
    Abdom Radiol (NY); 2019 Mar 01; 44(3):1083-1090. PubMed ID: 30539249
    [Abstract] [Full Text] [Related]

  • 15. Prognostic factors in metastatic non-seminomatous germ cell tumours: the Medical Research Council studies.
    Mead GM, Stenning SP.
    Eur Urol; 1993 Mar 01; 23(1):196-200; discussion 201. PubMed ID: 7682951
    [Abstract] [Full Text] [Related]

  • 16. Tissue alpha-fetoprotein and human chorionic gonadotrophin in non-seminomatous testicular tumours. A comparative study with serum levels.
    Altug MU, Akdas A, Ruacan S, Ozen AH, Remzi D.
    Br J Urol; 1987 May 01; 59(5):458-62. PubMed ID: 2439163
    [Abstract] [Full Text] [Related]

  • 17. Serum estradiol as a tumour marker for non-seminomatous germinal cell tumours (NSGCT) of the testis.
    Uysal Z, Bakkaloğlu M.
    Int Urol Nephrol; 1987 May 01; 19(4):415-8. PubMed ID: 2448261
    [Abstract] [Full Text] [Related]

  • 18. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment.
    Dieckmann KP, Simonsen-Richter H, Kulejewski M, Anheuser P, Zecha H, Isbarn H, Pichlmeier U.
    Biomed Res Int; 2019 May 01; 2019():5030349. PubMed ID: 31275973
    [Abstract] [Full Text] [Related]

  • 19. [Biological markers and germinal tumors of the testis. Value and limitations of the assay of chorionic gonadotrophin hormone and alpha-fetoprotein].
    Bassoulet J, Pabot du Chatelard P, Ricordel I, Auberget JL, Guillemot MC, Merrer J, Timbal Y.
    J Urol (Paris); 1988 May 01; 94(8):393-6. PubMed ID: 2467947
    [Abstract] [Full Text] [Related]

  • 20. Experience with serum alpha-fetoprotein and human chorionic gonadotropin in non-seminomatous testicular tumors.
    Fowler JE, Taylor G, Blom J, Stutzman RE.
    J Urol; 1980 Sep 01; 124(3):365-8. PubMed ID: 6159485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.